In:
International Journal of Cancer, Wiley, Vol. 139, No. 8 ( 2016-10-15), p. 1799-1809
Abstract:
What's new? Cytokine‐induced killer (CIK) cells are used in pre‐emptive immunotherapy for high‐risk cancer patients. In this study, the authors asked whether the cytotoxicity of CIK cells could be enhanced against B‐ALL. They engineered CIK cells to target a B‐cell‐specific antigen (CD19) by inserting a vector encoding a chimeric antigen receptor (CAR). Compared to controls, the targeted CIK cells were highly cytotoxic in vitro , and they also induced durable remissions in a mouse model of human B‐ALL. CAR‐engineered CIK cells may thus be a promising approach for immunotherapy of refractory leukemias.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8